Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice - Related Studies

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

This study has been completed.

Study NCT00007527. Last updated on June 23, 2005. Information provided by Department of Veterans Affairs

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Opiate Dependence

2	Additional conditions recognized in this trial
		Opioid-Related Disorders

3	More general conditions related to this trial
		Disorders of Environmental Origin
		Mental Disorders
		Substance-Related Disorders

4	Interventions listed in this trial
		naloxone
		buprenorphine

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Opioid
		Central Nervous System Agents
		Central Nervous System Depressants
		Narcotic Antagonists
		Narcotics
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Department of Veterans Affairs
		National Institute on Drug Abuse (NIDA)
		Reckitt and Colman